Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection

A retrospective nationwide study on the use of intravenous (IV) zanamivir in patients receiving intensive care who were pretreated with oseltamivir in the Netherlands was performed. In 6 of 13 patients with a sustained reduction of the viral load, the median time to start IV zanamivir was 9 days (ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Fraaij, P. L. A., van der Vries, E., Beersma, M. F. C., Riezebos-Brilman, A., Niesters, H. G. M., van der Eijk, A. A., de Jong, M. D., Reis Miranda, D., Horrevorts, A. M., Ridwan, B. U., Wolfhagen, M. J. H. M., Houmes, R. J., van Dissel, J. T., Fouchier, R. A. M., Kroes, A. C. M., Koopmans, M. P., Osterhaus, A. D. M. E., Boucher, C. A. B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156108/
https://www.ncbi.nlm.nih.gov/pubmed/21844304
http://dx.doi.org/10.1093/infdis/jir397
Descripción
Sumario:A retrospective nationwide study on the use of intravenous (IV) zanamivir in patients receiving intensive care who were pretreated with oseltamivir in the Netherlands was performed. In 6 of 13 patients with a sustained reduction of the viral load, the median time to start IV zanamivir was 9 days (range, 4–11 days) compared with 14 days (range, 6–21 days) in 7 patients without viral load reduction (P = .052). Viral load response did not influence mortality. We conclude that IV zanamivir as late add-on therapy has limited effectiveness. The effect of an immediate start with IV zanamivir monotherapy or in combination with other drugs need to be evaluated.

Ejemplares similares